Brian Gastman
Cleveland Clinic(US)Theravance Biopharma (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses, Nonmelanoma Skin Cancer Studies
Most-Cited Works
- → Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology(2019)436 cited
- → NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021(2021)330 cited
- → Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology(2018)314 cited
- → Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.(1998)239 cited
- → What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature(2010)226 cited
- → A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4–ERK5 axis(2015)224 cited
- Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.